Survival, efficacy, and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study.
Elena PezzoloDonatella SchenaAlessio GambardellaMariateresa RossiFrancesca BareiPiergiacomo Calzavara PintonGiampiero GirolomoniLuigi NaldiSilvia Mariel FerrucciPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)